The massive EPS miss is largely mechanical for a pre-revenue biotech (share count increased post-IPO), but the widening cash burn rate signals higher operating costs ahead of key catalysts. Watch for the Q4 2026 end-of-Phase 1 meeting with FDA for BH-30643, which could unlock an accelerated approval pathway and materially change the risk/reward.
Price Chart
Executive Summary
BlossomHill Therapeutics reported Q2 2026 net loss of $23.8M ($-8.75/share), significantly wider than the $-0.77 consensus estimate, driven by increased R&D spending on its SOLARA trial and IND-enabling studies. The company highlighted FDA Fast Track designation for BH-30643 and a strengthened balance sheet from its $168.3M IPO in August, extending cash runway into Q2 2028. The OrbiMed 13D filing (31 days prior) adds activist scrutiny context, but the earnings miss is the dominant near-term signal for this pre-revenue clinical-stage biotech.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $23.8M ($-8.75/share) vs consensus $-0.77 — a 1036% miss
- Revenue: $0 (pre-revenue clinical-stage company)
- R&D expenses rose to $21.4M from $12.5M YoY, driven by SOLARA trial and IND-enabling studies
- Cash and equivalents $95.4M at June 30; subsequent IPO raised $168.3M gross proceeds
- FDA Fast Track designation granted for BH-30643 in EGFR C797S-positive NSCLC
- OrbiMed Advisors disclosed a 13D activist stake on August 18, 2026
Financial Impact
Net loss of $23.8M vs consensus $-0.77 EPS — a 1036% miss; cash burn rate ~$8M/month pre-IPO; IPO proceeds extend runway into Q2 2028
Risk Factors
- Pre-revenue status with no approved products — all value depends on clinical trial outcomes
- Cash burn rate increased 70% YoY; IPO proceeds provide runway but future dilution risk remains
- Activist pressure from OrbiMed may push for strategic alternatives or pipeline prioritization
- BH-30643 Phase 2 pivotal trial not expected to start dosing until Q1 2027 — long catalyst timeline
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-395031 |
| Document: d266261d8k.htm | 0001193125-26-395031 |
| Document: 0001193125-26-395031-index-headers.html | 0001193125-26-395031 |
| Document: 0001193125-26-395031-index.html | 0001193125-26-395031 |
| Document: 0001193125-26-395031.txt | 0001193125-26-395031 |
| 8-K Data (Synthetic) | 0001193125-26-395031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | Press Release | $21.34 $16.39 | ▲ +23.20% | ▲ +23.16% | $14.63 (+31.44%) |
Sep 18, 2026 5w ago | 8-K | $25.74 $13.94 | ▲ +45.84% | ▲ +46.05% | $14.63 (+43.16%) |
Sep 18, 2026 5w ago | Press Release | $25.74 $13.94 | ▼ −45.84% | ▼ −46.05% | $14.63 (−43.16%) |
Sep 15, 2026 5w ago | 8-K | $22.17 $15.48 | ▼ −30.18% | ▼ −33.15% | $14.63 (−34.01%) |
Aug 12, 2026 10w ago | Insider Cluster | $16.35 $20.86 | ▲ +27.58% | ▲ +29.33% | $14.63 (−10.52%) |
Aug 10, 2026 11w ago | Insider Cluster | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $14.63 (−11.44%) |
Aug 10, 2026 11w ago | 8-K | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $14.63 (−11.44%) |
Aug 7, 2026 11w ago | 424B4 | $15.99 $22.93 | ▲ +43.40% | ▲ +44.32% | $14.63 (−8.51%) |
Aug 7, 2026 11w ago | EFFECT | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $14.63 (−8.56%) |
Aug 6, 2026 11w ago | 3 | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $14.63 (−8.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers